AustinPx, a contract development and manufacturing organisation (CDMO) specialising in bioavailability enhancement for orally delivered small molecule drugs, has been named the inaugural winner of the Advancing Pharmacy Research Award by The University of Texas at Austin College of Pharmacy.
The award recognises organisations and individuals who have made significant contributions to advancing pharmacy research and supporting the College’s mission.
The UT Austin College of Pharmacy, ranked No. 6 nationally by US News & World Report and among the top pharmacy programmes in the world, recognised AustinPx for its proprietary KinetiSol Technology, a disruptive drug delivery platform designed to overcome the solubility and formulation challenges of modern small molecule drug candidates.
KinetiSol was invented by AustinPx Chief Scientific Officer Dave Miller and Chief Technology Officer Chris Brough, who are both graduate students at the College of Pharmacy.
“As an Austin-based organisation with deep ties to UT, we are honoured to be recognised by the College of Pharmacy with this award, a testament to both AustinPx and UT’s impact on a local and global level,” said Elizabeth Hickman, Chief Executive Officer of AustinPx.
“Already adopted by most large pharmaceutical companies, we believe adoption of KinetiSol will only accelerate as our industry continues to confront molecules once considered undevelopable.”
KinetiSol is a solvent-free, fusion-based process that generates high-performance amorphous solid dispersions (ASD) in less than 20 seconds.
Its streamlined design and small operational footprint lead to faster development and a more cost-effective, scalable, and environmentally friendly ASD manufacturing process.
Owing to its broad formulation design space, KinetiSol supports thermally sensitive and poor solvent-soluble APIs, enabling compounds out of reach for existing technologies.
Beyond solubility enhancement, KinetiSol ASDs demonstrate improved flowability, compressibility, and ASD loading.
This recognition follows a series of industry honours for KinetiSol, including the Accelerating Innovation Award at the 2024 CPHI Pharma Awards and Best Technologies Innovation at Interphex 2024.
KinetiSol was also recently named as a finalist for the Sustainability Award at the 2025 CPHI Pharma Awards, where winners will be announced in late October.
Together, these accolades highlight growing industry adoption of KinetiSol as a breakthrough solution for complex molecules and challenging drug delivery needs.